cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester

We are cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester CAS:301-01-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester
Synonyms:CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC*ACID METHYL EST
CIS-4,7,10,13,16,19-DOCOSHEXAENOIC ACID METHYL ESTER
cis-4,7,10,13,16,19-docosahexaenoic*acid methyl E
cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester
 
CAS.NO: 301-01-9
Molecular Formula: C23H34O2
Molecular Weight: 342.51500
 
Physical and Chemical Properties:
Density: 0.917g / cm3
Boiling point: 429.9ºC at 760mmHg
Flash point: 103.9ºC
Refractive index: 1.504
 
Specification:
Appearance: liquid
Purity:≥99%
 
Packing:25KG / drum
Storage:Sealed and stored at -20 ºC
Application:For food and medicine

cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester


Related News: This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.N-(3-chloro-4-fluorophenyl)-7-(3-morpholin-4-ylpropoxy)-6-nitroquinazolin-4-amine Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as “bulk pharmaceutical chemicals (BPCs).”3-isocyanatopropyl(trimethoxy)silane CAS:15396-00-6 Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.benzothiazole Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms.The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.

Related Products
Product Name
2,2-Difluorocyclopropanecarboxylic acid Cas:107873-03-0 View Details
adenine arabinoside View Details
Ethyl 2-(1-Imidazolyl)acetate View Details
Tetra-(methylethylketoxime)silane manufacturer 6-Chloro-2-hexanone manufacturer 2-((fluoromethyl)sulfonyl)pyridine Cas:1365765-53-2 manufacturer TRITYL ISOTHIOCYANATE manufacturer 4-Methoxyphenylboronic acid manufacturer